We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ferritin Favors Tumor Growth by Blocking an Inhibitor of New Blood Vessel Formation

By LabMedica International staff writers
Posted on 14 Apr 2009
Print article
Image: Colored scanning electron micrograph (SEM) of prostate cancer cells (Photo courtesy of David McCarthy / SPL).
Image: Colored scanning electron micrograph (SEM) of prostate cancer cells (Photo courtesy of David McCarthy / SPL).
Cancer researchers have found that the serum iron transport protein ferritin stimulates tumor growth and expansion by blocking the antiangiogenic activity of another blood protein, HKa (cleaved high molecular weight kininogen).

The current study was prompted by findings that ferritin levels were often elevated in cancer patients. "It has been known for a long time that levels of ferritin are increased in people with tumors, but it has never been understood why that happens," explained senior author Dr. Suzy V. Torti, associate professor of biochemistry at Wake Forest University (Winston-Salem, NC, USA). "Ferritin appears to play an important role in blood vessel formation. Further, the interaction between ferritin and HKa may represent a new area of interest for possible drug development."

The investigators worked with a line of immunocompromised mice into which they transplanted cells from human prostate tumors. They reported in the January 6, 2009, online edition of the journal the Proceedings of the [U.S.] National Academy of Sciences (PNAS) that ferritin bound to HKa with high affinity and that ferritin blocked the antiangiogenic effects of Hka. This interaction, which was independent of ferritin's iron content, enhanced the migration, assembly, and survival of HKa-treated endothelial cells. Peptide mapping revealed that ferritin bound to a 22-amino acid subdomain of HKa that was critical to its antiangiogenic activity.

In the mouse xenograft study, coinjection of Hka and cancer cells produced small tumors with inhibited blood vessel formation. However, addition of ferritin to the mixture of HKa and cancer cells restored blood vessel formation, promoting tumor growth.

"Blood vessels can either be helpful, for example in wound healing, or they can be harmful, for example by favoring tumor growth," said Dr. Torti. "Our new finding is that the interaction between ferritin and HKa can influence blood vessel formation. This finding could serve as the basis for strategies to either inhibit or stimulate blood vessels. This opens up a new realm of potential ways to treat tumors or other conditions that depend on new blood vessel formation."

Related Links:
Wake Forest University


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.